Actinic keratosis

Approximately 3 months after photodynamic therapy (PDT), the treated skin areas should be re-examined to assess the success of the treatment. Any remaining lesions can then be treated again with PDT.1

Actinic Keratosis (AK) constitutes a chronic disease. Where AKs are multiple or confluent or at sites of poor healing, patients may warrant long-term follow-up for the associated increased risk of NMSC.2

Regular screening at 6 month intervals is also recommended for patients taking immunosuppressive medications who have a high incidence of AK and skin cancer.3

Basal cell carcinoma

Patients treated with PDT should be reassessed after 3 months and any lesions which have not completely resolved should be re-treated.1

Patients who have once developed a basal cell carcinoma (BCC) have a significantly higher risk of developing a further BCC.4 In addition, such patients are also at risk with regard to the development of further skin tumors, such as squamous cell carcinoma.4 Regular follow-up is therefore important for the early detection of local recurrences and second tumors.

The design of the follow-up depends on the risk of recurrence and the number of basal cell carcinomas treated5:

  • Do not routinely offer follow-up to patients with adequately treated isolated BCC.
  • Offer, if possible, at least yearly follow-up to adults with a history of multiple BCCs who are likely to develop further tumours or recurrence within 12 months.

This may need to be more frequent in selected high-risk patients such as those with Gorlin-Goltz syndrome or immunosuppressed organ transplant recipients.

 

Patients with a high risk of developing skin cancer such as those with Gorlin-Goltz syndrome are advised to protect themselves from UV light through a combination of avoiding sunlight exposure, wearing appropriate clothing and the use of sunscreen.5

Generally speaking: In addition to regular follow-up as part of skin cancer screening, physicians should instruct their patients to perform regular self-inspection of their skin.
Conspicuous skin changes should then be clarified by a doctor as soon as possible.

References

  1. Ameluz® Summary of Product Characteristics
  2. D. de Berker, et al. Br J Dermatol 2017 Jan;176(1):20-43
  3. Stasko et al Dermatol Surg 2004 30:4 Part 2: pp 642-650
  4. Flohil SC et al. Eur J Cancer 2013;49:2365-2375.
  5. Nasr et al. British Journal of Dermatology 2021 Nov;185(5):899-920.
  6. https://www.cancerresearchuk.org/about-cancer/other-conditions/gorlin-syndrome - accessed November 2022

UKBF-2022-006l-V01, Date of preparation: April 2022